Blocking the complement system as a therapeutic strategy has been proposed for numerous glomerular diseases but presents myriad questions and challenges, not the least of which is demonstrating efficacy and safety. In light of these potential issues and because there are an increasing number of anticomplement therapy trials either planned or under way, the National Kidney Foundation facilitated an all-virtual scientific workshop entitled "Improving Clinical Trials for Anti-Complement Therapies in Complement-Mediated Glomerulopathies." Attended by patient representatives and experts in glomerular diseases, complement physiology, and clinical trial design, the aim of this workshop was to develop standards applicable for designing and conducting clinical trials for anticomplement therapies across a wide spectrum of complement-mediated glomerulopathies. Discussions focused on study design, participant risk assessment and mitigation, laboratory measurements and biomarkers to support these studies, and identification of optimal outcome measures to detect benefit, specifically for trials in complement-mediated diseases. This report summarizes the discussions from this workshop and outlines consensus recommendations.
Keywords: Glomerular disease; clinical trial design; complement biomarkers; complement blockade; complement inhibition; complement-mediated glomerulopathy; drug approval pathway; drug safety; glomerulonephritides; infectious risk; patient-reported outcome (PRO); rare diseases; research priorities; surrogate outcome; trial end points.
Copyright © 2021 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.